Linked Life Data

19169957

Source:http://linkedlifedata.com/resource/pubmed/id/19169957

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-1-26
pubmed:abstractText
Numerous research groups are investigating the use of cancer vaccines as a potential therapeutic modality for various tumor types. The efficacy of cancer vaccines has improved because of advances in the characterization of tumor-associated antigens, the development of improved vaccine delivery systems, and the combination of vaccines with cytokines and other immunostimulants to enhance immune responses. Although cancer vaccines are under investigation for the treatment of various different tumor types, several characteristics of prostate cancer make it an ideal target for immunotherapy. The relative indolence of prostrate cancer allows sufficient time to generate immune responses, which usually take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal tissue. This review focuses on promising new strategies for combining vaccines with other therapeutic approaches, as well as novel perspectives in the treatment of prostate cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
2040-3445
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
31-6
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Cancer vaccines: current directions and perspectives in prostate cancer.
pubmed:affiliation
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
pubmed:publicationType
Journal Article, Review